Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.6 EUR | -0.71% | +12.00% | +30.84% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.39M | Sales 2024 * | 37.83M 40.57M | Capitalization | 121M 130M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.66M | Net income 2024 * | -5M -5.36M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 36.14M | Net Debt 2024 * | 46.6M 49.97M | EV / Sales 2024 * | 4.42 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-13
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | -0.71% | ||
1 week | +12.00% | ||
Current month | +15.23% | ||
1 month | +16.67% | ||
3 months | +43.59% | ||
6 months | +33.33% | ||
Current year | +30.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 5.6 | -0.71% | 158,909 |
24-04-24 | 5.64 | -5.53% | 240,936 |
24-04-23 | 5.97 | 0.00% | 376,959 |
24-04-22 | 5.97 | +10.97% | 410,921 |
24-04-19 | 5.38 | +7.60% | 328,456 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.84% | 130M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- OSE Stock